blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3139951

EP3139951 - VACCINE FOR PREVENTION OF LYME BORRELIOSIS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  16.07.2021
Database last updated on 11.09.2024
FormerThe patent has been granted
Status updated on  07.08.2020
FormerGrant of patent is intended
Status updated on  23.04.2020
FormerExamination is in progress
Status updated on  16.02.2018
FormerRequest for examination was made
Status updated on  10.02.2017
FormerThe international publication has been made
Status updated on  11.11.2016
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024 [2024/41]
Applicant(s)For all designated states
Vyzkumny ústav veterinárního lékarství, v.v.i.
Hudcova 296/70
621 00 Brno / CZ
For all designated states
Univerzita Palackého v Olomouci
Krízkovského 511/8
771 47 Olomouc / CZ
For all designated states
Bioveta, A.S.
Komenskeho 212/12
68323 Ivanovice na Hane / CZ
For all designated states
Ustav organicke chemie a biochemie AV CR, v.v.i.
Flemingovo nam. 542/2
166 10 Praha 6 / CZ
For all designated states
Fyzikální ústav AV CR, v.v.i.
Na Slovance 2
18221 Praha 8 / CZ
[2017/11]
Inventor(s)01 / TURANEK, Jaroslav
Brechtova 13
63800 Brno-Lesna / CZ
02 / MASEK, Josef
Nejedleho 1
63800 Brno-Lesna / CZ
03 / RASKA, Milan
Stupkova 7
77900 Olomouc / CZ
04 / WEIGL, Evzen
Trnkova 13
77900 Olomouc / CZ
05 / KRUPKA, Michal
Brnenska 42
77900 Olomouc / CZ
06 / BITTNER, Libor
Sidliste Osvobozeni 651/35
68201 Vyskov-Dedice / CZ
07 / NEPERENY, Jiri
Druzstevni 96/2
68201 Vyskov-Nosalovice / CZ
08 / VRZAL, Vladimir
Malinovskeho 767/39
68323 Ivanovice na Hane / CZ
09 / LEDVINA, Miroslav
Brezinova 513/2
18600 Praha 8 / CZ
10 / KRATOCHVILOVA, Irena
K Haltyri 689/16
18100 Praha 8-Troja / CZ
 [2017/11]
Representative(s)Hartvichova, Katerina, et al
HARBER IP s.r.o.
Dukelskych hrdinu 567/52
170 00 Praha 7 / CZ
[2020/37]
Former [2017/11]Hartvichova, Katerina
Inventia s.r.o.
Na Belidle 3
150 00 Praha 5 / CZ
Application number, filing date15727869.811.05.2015
[2017/11]
WO2015CZ00042
Priority number, dateCZ2014000032009.05.2014         Original published format: CZ 20140320
[2017/11]
Filing languageCS
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015169271
Date:12.11.2015
Language:EN
[2015/45]
Type: A1 Application with search report 
No.:EP3139951
Date:15.03.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 12.11.2015 takes the place of the publication of the European patent application.
[2017/11]
Type: B1 Patent specification 
No.:EP3139951
Date:09.09.2020
Language:EN
[2020/37]
Search report(s)International search report - published on:EP12.11.2015
ClassificationIPC:A61K39/02, C07K14/20, A61K39/00
[2017/11]
CPC:
C07K16/1207 (EP); C07K16/18 (EP); A61K2039/70 (EP);
A61K39/0225 (EP); C07K2319/00 (EP); Y02A50/30 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/11]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:IMPFSTOFF ZUR PRÄVENTION VON LYME-BORRELIOSE[2017/11]
English:VACCINE FOR PREVENTION OF LYME BORRELIOSIS[2017/11]
French:VACCIN POUR LA PRÉVENTION DE LA BORRÉLIOSE DE LYME[2017/11]
Entry into regional phase11.11.2016National basic fee paid 
11.11.2016Designation fee(s) paid 
11.11.2016Examination fee paid 
Examination procedure11.11.2016Examination requested  [2017/11]
11.11.2016Date on which the examining division has become responsible
31.07.2017Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
22.09.2017Amendment by applicant (claims and/or description)
16.02.2018Despatch of a communication from the examining division (Time limit: M04)
20.06.2018Reply to a communication from the examining division
25.10.2018Despatch of a communication from the examining division (Time limit: M06)
02.05.2019Reply to a communication from the examining division
24.04.2020Communication of intention to grant the patent
02.08.2020Fee for grant paid
02.08.2020Fee for publishing/printing paid
02.08.2020Receipt of the translation of the claim(s)
Opposition(s)10.06.2021No opposition filed within time limit [2021/33]
Request for further processing for:22.09.2017Request for further processing filed
22.09.2017Full payment received (date of receipt of payment)
Request granted
02.10.2017Decision despatched
Fees paidRenewal fee
10.05.2017Renewal fee patent year 03
29.03.2018Renewal fee patent year 04
10.05.2019Renewal fee patent year 05
03.04.2020Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU11.05.2015
AL09.09.2020
AT09.09.2020
CY09.09.2020
DK09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
IT09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
MK09.09.2020
MT09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
TR09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
IE11.05.2021
LU11.05.2021
BE31.05.2021
CH31.05.2021
LI31.05.2021
[2024/41]
Former [2024/29]HU11.05.2015
AL09.09.2020
AT09.09.2020
CY09.09.2020
DK09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
IT09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
MK09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
TR09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
IE11.05.2021
LU11.05.2021
BE31.05.2021
CH31.05.2021
LI31.05.2021
Former [2024/22]HU11.05.2015
AL09.09.2020
AT09.09.2020
CY09.09.2020
DK09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
IT09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
MK09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
IE11.05.2021
LU11.05.2021
BE31.05.2021
CH31.05.2021
LI31.05.2021
Former [2023/30]HU11.05.2015
AL09.09.2020
AT09.09.2020
CY09.09.2020
DK09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
IT09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
IE11.05.2021
LU11.05.2021
BE31.05.2021
CH31.05.2021
LI31.05.2021
Former [2023/29]HU11.05.2015
AL09.09.2020
AT09.09.2020
DK09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
IT09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
IE11.05.2021
LU11.05.2021
BE31.05.2021
CH31.05.2021
LI31.05.2021
Former [2022/34]AL09.09.2020
AT09.09.2020
DK09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
IT09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
IE11.05.2021
LU11.05.2021
BE31.05.2021
CH31.05.2021
LI31.05.2021
Former [2022/21]AL09.09.2020
AT09.09.2020
DK09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
IT09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
IE11.05.2021
LU11.05.2021
CH31.05.2021
LI31.05.2021
Former [2022/11]AL09.09.2020
AT09.09.2020
DK09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
IT09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
LU11.05.2021
CH31.05.2021
LI31.05.2021
Former [2022/09]AL09.09.2020
AT09.09.2020
DK09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
IT09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
LU11.05.2021
Former [2022/07]AL09.09.2020
AT09.09.2020
DK09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
IT09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/48]AL09.09.2020
AT09.09.2020
DK09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
IT09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/37]AL09.09.2020
AT09.09.2020
DK09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/36]AL09.09.2020
AT09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/28]AL09.09.2020
AT09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/25]AL09.09.2020
AT09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/23]AT09.09.2020
EE09.09.2020
FI09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
PT11.01.2021
Former [2021/22]EE09.09.2020
FI09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
PT11.01.2021
Former [2021/21]FI09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RS09.09.2020
SE09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
PT11.01.2021
Former [2021/18]FI09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RS09.09.2020
SE09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
Former [2021/10]FI09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
PL09.09.2020
RS09.09.2020
SE09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
Former [2021/09]FI09.09.2020
LT09.09.2020
SE09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
Former [2021/08]FI09.09.2020
LT09.09.2020
SE09.09.2020
BG09.12.2020
NO09.12.2020
Former [2021/07]FI09.09.2020
LT09.09.2020
NO09.12.2020
Cited inInternational search[X]WO9512676  (ASS UNIVERSITIES INC [US]) [X] 1,4-9 * the whole document * * see in particular abstract; pages 48-50; table III on page 52; claims 1-4, 6, 14, 43-48 *;
 [I]WO2007065098  (UNIV VIRGINIA COMMONWEALTH [US], et al) [I] 1-3,7-9 * the whole document * * see in particular abstract; Examples 3-4; pages 65-66; Figures 13A-E, 15-17; claims 1-18, 28*;
 [X]WO2011143617  (BAXTER INT [US], et al) [X] 1,4-9 * the whole document * * see in particular abstract, Examples 3-5, 9-11, 12-17 and 19-22 *;
 [I]WO2012054580  (UNIV VIRGINIA COMMONWEALTH [US], et al) [I] 1-3,7-9 * the whole document * * see in particular abstract; Examples 1-4; claims 1-18 *;
 [I]WO2014018274  (BAXTER INT [US], et al) [I] 1,4-9 * the whole document * * see in particular abstract, Examples 3-6, 9-17, 19-24; Figures 21-23 *;
 [I]  - Michal Krupka ET AL, "Recombinant polyepitop-forming chimera protein derived from Borrelia burgdorferi OspC variants induces specific antibodies recognizing wide spectrum of antigenic variants of pathogenic Borreliae.", (20130822), URL: http://www.frontiersin.org/10.3389/conf.fimmu.2013.02.00469/event_abstract, (20150708), XP055201147 [I] 1-3,7-9 * the whole document *

DOI:   http://dx.doi.org/10.3389/conf.fimmu.2013.02.00469
 [I]  - EARNHART ET AL, "Construction and analysis of variants of a polyvalent Lyme disease vaccine: Approaches for improving the immune response to chimeric vaccinogens", VACCINE, ELSEVIER LTD, GB, (20070405), vol. 25, no. 17, doi:10.1016/J.VACCINE.2006.12.051, ISSN 0264-410X, pages 3419 - 3427, XP022022120 [I] 1-3,7-9 * the whole document * * see in particular abstract; pages 3423-26; Figures 1, 5 *

DOI:   http://dx.doi.org/10.1016/j.vaccine.2006.12.051
 [I]  - Christopher G. Earnhart ET AL, "An Octavalent Lyme Disease Vaccine Induces Antibodies That Recognize All Incorporated ospC Type-Specific Sequences", Human Vaccines, (20071101), pages 281 - 289, URL: http://www.landesbioscience.com/journals/vaccines/article/4661/, (20150723), XP055100831 [I] 1-3,7-9 * the whole document * * see in particular abstract; pages 282-287; Figures 1-3 *

DOI:   http://dx.doi.org/10.4161/hv.4661
 [A]  - C. G. EARNHART ET AL, "Demonstration of OspC Type Diversity in Invasive Human Lyme Disease Isolates and Identification of Previously Uncharacterized Epitopes That Define the Specificity of the OspC Murine Antibody Response", INFECTION AND IMMUNITY, (20051118), vol. 73, no. 12, doi:10.1128/IAI.73.12.7869-7877.2005, ISSN 0019-9567, pages 7869 - 7877, XP055199803 [A] 1-3,7-9 * the whole document *

DOI:   http://dx.doi.org/10.1128/IAI.73.12.7869-7877.2005
 [A]  - MICHAL K UPKA ET AL, "Enhancement of immune response towards non-lipidizedrecombinant OspC antigen by binding onto the surface of metallochelating nanoliposomes with entrapped lipophilic derivatives of norAbuMDP", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 160, no. 2, doi:10.1016/J.JCONREL.2012.02.017, ISSN 0168-3659, (20120218), pages 374 - 381, (20120222), XP028512654 [A] 1-3,7-9 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.jconrel.2012.02.017
 [I]  - NINA WRESSNIGG ET AL, "Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial", LANCET INFECTIOUS DISEASES, ELSEVIER LTD, US, vol. 13, no. 8, doi:10.1016/S1473-3099(13)70110-5, ISSN 1473-3099, (20130801), pages 680 - 689, (20130510), XP002714295 [I] 1,4-9 * the whole document * * see in particular abstract; page 681-82; 686-88; table 4 *

DOI:   http://dx.doi.org/10.1016/S1473-3099(13)70110-5
 [I]  - P NOEL BARRETT ET AL, "A novel multivalent OspA vaccine against Lyme borreliosis shows promise in Phase I/II studies", EXPERT REVIEW OF VACCINES, (20130901), vol. 12, no. 9, doi:10.1586/14760584.2013.824704, ISSN 1476-0584, pages 973 - 975, XP055218377 [I] 1,4-9 * the whole document * * see in particular abstract, page 974 *

DOI:   http://dx.doi.org/10.1586/14760584.2013.824704
 [A]  - DING W ET AL, "Structural identification of a key protective B-cell epitope in lyme disease antigen OspA", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, (20001006), vol. 302, no. 5, doi:10.1006/JMBI.2000.4119, ISSN 0022-2836, pages 1153 - 1164, XP004472344 [A] 1,4-9 * the whole document *

DOI:   http://dx.doi.org/10.1006/jmbi.2000.4119
ExaminationWO0216422
    - LUFT B J ET AL, "A NEW MULTI-TARGET OSPA-OSPC VACCINE FOR LYME DISEASE", ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTSAND CHEMOTHER, XX, XX, (20000917), vol. 40, XP008004693
by applicantWO2009115782
    - BARBOUR AG; FISH D, SCIENCE, (19930611), vol. 260, no. 5114, pages 1610 - 6
    - BARTUNEK P. HISTORIE; BARTUNEK P. ET AL., Lymeská borelioza, PRAHA: GRADA PUBLISHING,, (2006), vol. 11
    - BURGDORFER W; BARBOUR AG; HAYES SF; BENACH JL; GRUNWALDT E; DAVIS JP, SCIENCE, (1982), vol. 216, pages 1317 - 1319
    - KUMARU OS; SCHULZE RJ; RODNIN MV; LADOKHIN AS; ZUCKERT WR, J BACTERIOL, (201106), vol. 193, no. 11, pages 2814 - 25
    - LIVEY I; O'ROURKE M; TRAWEGER A; SAVIDIS-DACHO H; CROWE BA; BARRETT PN; YANG X; DUNN JJ; LUFT BJ, CLIN INFECT DIS, (201102), vol. 52, no. 3, pages 266 - 70
    - CHEN S; ZUCKERT WR., J BACTERIOL., (201112), vol. 193, no. 23, pages 6724 - 32
    - TILLY K; BESTOR A; ROSA PA, MOL MICROBIOL., (201307), vol. 89, no. 2, pages 216 - 27
    - GILMORE RD, INFECT IMMUN, (1996), vol. 64, pages 2234 - 2239
    - OBONYO M; MUNDERLOH UG; FINGERLE V; WILSKE B; KURTTI TJ, J CLINMICROBIOL, (199907), vol. 37, no. 7, pages 2137 - 41
    - XU Q; MCSHAN K; LIANG FT, MICROBIOLOGY, (200811), vol. 154, pages 3420 - 9
    - BARBOUR ET AL., INFECT IMMUN., (1983), vol. 41, no. 2, pages 795 - 804
    - HOWE ET AL., SCIENCE, (1985), vol. 227, no. 4687, pages 645 - 6
    - LAHTEENMAKI ET AL., FEMS MICROBIOL REV., (2001), vol. 25, no. 5, pages 531 - 52
    - PREAC-MURSIC, WILSKE ET AL., INFECTION, (1992), vol. 20, no. 6, pages 342 - 9
    - MARCONI, RT; SAMUELS, DS; GARON, CF, JBACTERIOL., (1993), vol. 175, no. 926, page 1.932
    - PREAC-MURSIC V; WILSKE B; PATSOURIS E ET AL., INFECTION, (1992), vol. 20, pages 342 - 349
    - SEINOST, G.,SCHRIEFER. M E AND LUFL, B. J, INFECT. IMMUN., (1999), vol. 67, pages 3518 - 3524
    - LEVY SA; LISSMAN BA; FICKE CM, JAM VET MED ASSOC., (19930601), vol. 202, no. 11, pages 1834 - 8
    - WORMSER, GP, ANN INTERN MED, (1995), vol. 123, pages 627 - 629
    - FIKRIG E ET AL., SCIENCE, (19901026), vol. 250, no. 4980, pages 553 - 6
    - FIKRIG E ET AL., INFECT LMMUN., (199203), vol. 60, no. 3, pages 773 - 7
    - KELLER D ET AL., JAMA, (19920615), vol. 271, no. 22, pages 1764 - 8
    - FIKRIG E ET AL., PROCNATLACADSCI USA, vol. 89, no. 12, pages 5418 - 21
    - STEEREAC ET AL., N ENGL J MED., (19980723), vol. 339, no. 4, pages 209 - 15
    - HAJDUSEK ET AL., VACCINE, (2010), vol. 28, pages 2993 - 2998
    - LEDVINA M; JEZEK J; SAMAN D.; HRIBALOVA V, COLLECT. CZECH. CHEM. COMMUN., (1998), vol. 63, pages 590 - 598
    - LEDVINA M; ZYKA D.; JEZEK J; TRNKA T; SAMAN D., COLLECT. CZECH. CHEM. COMMUN., (1998), vol. 63, pages 577 - 589
    - TURANEK J; MASEK J; RASKA M; LEDVINA M, Biomedical Science, Engineering and Technology, Application of Liposomes for Construction of Vaccines, INTECH, (201201), pages 653 - 678
    - GREGORIADIS; ALLISON, NATURE, (1974), vol. 252, page 252
    - KRUPKA ET AL., JOURNAL OF CONTROLLED RELEASE, (2012), vol. 160, pages 374 - 381
    - MASEK ET AL., ANALYTICAL BIOCHEMISTRY, (2011), vol. 408, pages 95 - 104
    - KOPACEK ET AL., INSECT BIOCHEMISTRY AND MOLECULAR BIOLOGY, (2003), vol. 33, pages 103 - 113
    - GALAY ET AL., PLOS ONE, (2014), vol. 9, page E90661
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.